8-K: Cara Therapeutics Addresses Stockholder Lawsuits and Demands Related to Tvardi Therapeutics Merger

Cara Therapeutics provides supplemental disclosures to its proxy statement/prospectus regarding the merger with Tvardi Therapeutics in response to stockholder demands and lawsuits alleging materially false and misleading statements.

Summary

• Cara Therapeutics is providing supplemental disclosures related to its merger with Tvardi Therapeutics in response to thirteen demands and two lawsuits from purported Cara stockholders.
• The lawsuits allege that the registration statement contains materially false and misleading statements.
• Cara denies any violations of law or breaches of duty but is providing the supplemental disclosures to avoid the burden and expense of litigation and potential disruption to the merger.
• The supplemental disclosures include updates to the sections on directors of the combined company, legal proceedings, ownership interest, securities litigation risks, lawsuits against Cara, the background of the merger, selected public companies analysis, selected IPO analysis, and composition of the board of directors following the merger.
• The combined company's board will consist of seven directors: five designated by Tvardi, one by Cara (Susan Shiff), and one vacancy to be designated later.
• Piper Sandler reviewed comparable companies and IPOs to analyze Tvardi's value, considering factors like market capitalization, enterprise value, and development stage.
• Cara urges stockholders to read the proxy statement/prospectus in its entirety and submit their proxies promptly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the merger is proceeding, the lawsuits and demands introduce uncertainty and potential risks. The company is taking steps to address these issues, but the overall outlook is neither overwhelmingly positive nor negative.

Positives

• Cara is proactively addressing stockholder concerns by providing supplemental disclosures.
• The company is taking steps to minimize potential disruptions to the merger process.
• The supplemental disclosures provide additional information to stockholders for their consideration.

Negatives

• The lawsuits and demands from stockholders indicate potential dissatisfaction with the merger disclosures.
• The need for supplemental disclosures suggests possible deficiencies in the initial registration statement.
• Legal proceedings could divert management's attention and resources.

Risks

• Additional lawsuits may be filed against Cara, Merger Sub, Tvardi, and/or the Cara Board.
• The outcome of the litigation is uncertain, and Cara may not be successful in defending against current or future claims.
• Litigation could delay or prevent the merger, divert management's attention, and adversely affect Cara's financial condition.
• The combined company may become involved in securities litigation that could divert management's attention and harm the combined company's business.

Future Outlook

The document contains forward-looking statements regarding the anticipated completion and effects of the proposed Merger, and cautions that actual results may differ materially due to various risks and uncertainties.

Management Comments

• Cara and the other named defendants deny that they have violated any laws or breached any duties to stockholders of Cara.
• Cara believes that no supplemental disclosure is required to the proxy statement/prospectus under any applicable law, rule or regulation.
• Cara is providing certain supplemental disclosures solely to eliminate the burden and expense of litigation and to avoid any possible disruption to the Merger.

Industry Context

The document highlights the trend of companies facing stockholder litigation following significant business transactions like mergers, which is a common occurrence in the biopharmaceutical industry.

Comparison to Industry Standards

• Piper Sandler's analysis compared Tvardi to public companies like Pliant Therapeutics, Trevi Therapeutics, and Contineum Therapeutics in the idiopathic pulmonary fibrosis (IPF) space.
• The analysis also included comparisons to companies like Upstream Bio, Dianthus Therapeutics, and Tourmaline Bio in the inflammation and immunology (I&I) space.
• Additionally, the analysis considered oncology companies like Leap Therapeutics, Protara Therapeutics, and Black Diamond Therapeutics.
• The IPO analysis included companies like Upstream Bio, HilleVax, and CinCor Pharma, focusing on single clinical-stage assets or IPF-targeting assets.

Legal Proceedings

• Two lawsuits were filed in the Supreme Court of the State of New York, County of New York on March 5 and March 6, 2025 by two purported stockholders of Cara in connection with the Merger.
• Between December 18, 2024 and March 24, 2025, Cara received thirteen demands and three draft complaints from purported stockholders of Cara making substantially similar claims as in the Complaints regarding the disclosures in the proxy statement/prospectus related to the Merger.
• Additional lawsuits may be filed against Cara, Merger Sub, Tvardi, and/or the Cara Board, and additional demands may be received in connection with the Merger and the proxy statement/prospectus.

Stakeholder Impact

• Shareholders are impacted by the potential dilution of ownership and voting interest in the combined company.
• The lawsuits and demands could affect the value of Cara's stock.
• Employees may be affected by changes in management and board composition following the merger.

Next Steps

• Cara stockholders are urged to read the proxy statement/prospectus and submit their proxies promptly.
• The company will continue to defend against the lawsuits and demands.
• The parties will work to satisfy the conditions for closing the merger.

Key Dates

Keywords

Merger, Tvardi Therapeutics, Cara Therapeutics, Lawsuits, Proxy Statement, Disclosures, Stockholders, Registration Statement